AbbVie is expanding its presence in North Chicago, Illinois, with a new $195 million manufacturing facility expected to produce active pharmaceutical ingredients. The project is part of the company’s larger $10 billion investment plan for the US, which aims to support future medical breakthroughs and maintain leadership in pharmaceutical innovation.
The new facility will be operational by 2027 and will enable AbbVie to produce current and next-gen therapies in neuroscience, immunology, and oncology. The expansion is expected to add to the company’s existing workforce of over 6,000 people at 11 US manufacturing sites, although the exact number of additional jobs is not disclosed.
AbbVie CEO Robert Michael stated that the project is crucial for delivering next-generation medicines that make a significant impact on patients’ lives. This comes as other major pharmaceutical companies, including Johnson & Johnson and Eli Lilly, have pledged to spend tens of billions of dollars on US-based production operations in response to looming tariffs on imported pharmaceuticals.
The US pharma industry is facing increasing pressure due to the threat of tariffs, with President Trump announcing plans to impose 250% tariffs on pharmaceutical imports. This has prompted companies like AbbVie to accelerate their investment plans and expand their domestic manufacturing capabilities.
Source: https://www.fiercepharma.com/manufacturing/abbvie-plans-195m-api-plant-illinois-part-us-investment-campaign